 |
The ABPI Code of Practice 2006 The implications for medical sales |
The new ABPI Code of Practice, which comes into effect from
1 January 2006, is the first major review of the Code for ten
years, and is the result of a lengthy and comprehensive review that
has included consultation with companies and a broad range of
stakeholders. The new Code takes into account the changes to
European and UK legislation ... |
|
|
|
|
|
|
|
 |
Medicines Appraisal in Wales An obstacle or an opportunity? |
Healthcare technology assessments (HTA)
use existing evidence to evaluate the
clinical effectiveness, cost-effectiveness
and broader impact of a health technology
on patients and the healthcare
system. The use and development of
HTA are growing, due to the cost pressures
imposed by an ageing population, rising
societal expectations and ... |
|
|
|
Something Special Maximising your personal brand |
 |
We all know that a company needs a powerful brand in order to sell
itself and its products or services . . . and you, as an individual, are no
different. You are on the path to success and progr ... |
|
|
|
 |
Disease Management in Europe The opportunities for the pharmaceutical industry |
Although they are only a little more than a decade old, disease
management (DM) programmes are already starting to show their
worth. Designed with two key goals in mind reducing healthcare
costs and improving the quality of life through better co-ordination
of medication and increased education about healthy living DM
programmes are just ... |
|
|
|
|
|
|
|
 |
Shifting the Mindset How to manage through change |
Change is inevitable, and one current change having a major
impact on pharmaceutical sales management is the reduction in the
number of PCTs from 303 to 180. The SHA has until October 2006
to provide the next generation of PCTs, which must deliver a 15%
reduction in managerial and administration costs. |
|
|
|
|
|